- from the group consisting of:
  - a) a RANKL polypeptide comprising amino acids 69-313 of SEQ ID NO:13;
  - b) a RANKL polypeptide comprising amino acids 1-162 of SEQ ID NO:13;
  - c) a RANKL polypeptide comprising amino acids 162-313 of SEQ ID

NO:13;

- d) a RANKL polypeptide comprising amino acids 138-317 of SEQ ID NO:13; and
- e) a RANKL polypeptide comprising amino acids x to y of SEQ ID NO:13, wherein x is an amino terminal amino acid between 69 and 162 of SEQ ID NO:13, and y is a carboxy terminal amino acid between 313 and 317 of SEQ ID NO:13.
- 43. (New) An antibody according to claim 42 which is a monoclonal antibody.
- 44. (New) An antibody according to claim 43, wherein the RANKL polypeptide comprises amino acids 69-313 of SEQ ID NO:13.
- 45. (New) An antibody according to claim 43, wherein the RANKL polypeptide comprises amino acids 1-162 of SEQ ID NO:13.
- 46. (New) An antibody according to claim 43, wherein the RANKL polypeptide comprises amino acids 162-313 of SEQ ID NO:13.
- 47. (New) An antibody according to claim 43, wherein the RANKL polypeptide comprises amino acids 138-317 of SEQ ID NO:13.
  - 48. (New) A composition comprising an antibody according to claim 36.
  - 49. (New) A composition comprising an antibody according to claim 43. --

## In the Abstract:

Please delete the Abstract at page 74, lines 4-6 and substitute therefor the following Abstract:

-- Provided herein are antibodies that bind human RANKL polypeptides. --

B10